LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4/MyD88/NF-kappaB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research[1][2].
Molekulargewicht:
497.57
CAS Nummer:
[2249864-11-5]
Formel:
C24H27N5O5S
Target-Kategorie:
Collagen,MyD88,NF-kappaB,p38 MAPK,Reactive Oxygen Species (ROS),TGF-beta Receptor,Toll-like Receptor (TLR)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
